Ticker

SELLAS Life Sciences Group, Inc. (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The consensus price target hints at a 63.6% upside potential for SELLAS Life Sciences Group, Inc. (SLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report) shares gapped up before the market opened on Friday following a better than expected earnings announcement. The stock had previously closed at $5.20, but opened at $5.60. SELLAS Life Sciences Group shares last traded at $5.4990, with a volume of 2,307,376 shares traded. The company

A late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, SELLAS Life Sciences Group ( NASDAQ:SLS ) is at a genuinely unusual inflection point.

SELLAS Life Sciences Group (NASDAQ: SLS - Get Free Report) and Dianthus Therapeutics (NASDAQ: DNTH - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability. Profitability This table compares SELLAS Life